In rheumatic heart disease–associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y.
- Resource Type
- Article
- Authors
- Lader, Ellis W.
- Source
- Annals of Internal Medicine. Jan2023, Vol. 176 Issue 1, pJC2-JC2. 1p. 1 Chart.
- Subject
- *RIVAROXABAN
*ATRIAL fibrillation
*HEART
*BIBLIOGRAPHICAL citations
- Language
- ISSN
- 0003-4819
Source Citation: Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease–associated atrial fibrillation. N Engl J Med. 2022;387:978-88. 36036525 Clinical Impact Ratings: Cardiology: [ABSTRACT FROM AUTHOR]